胃癌术前放化疗正常组织放射损伤的剂量效应分析

doi:10.3760/cma.j.issn.1004-4221.2018.03.009

摘要
图/表
参考文献()
相关文章 (2)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的分析影响胃癌术前放化疗正常组织损伤的临床和剂量体积因素,为优化3DRT计划提供参考。方法分析 58例完成新辅助治疗的局部进展期胃腺癌术前放化疗联合手术及辅助化疗或术前化疗联合手术及辅助化疗的患者。术前化疗组(28例):术前xelox (卡培他滨+奥沙利铂)方案 2~3程,术后xelox方案 3~4程(共6程)。术前放化疗组(30例):首程xelox化疗后第 14—21天内开始3DRT (45 Gy分25次),同期2程xelox化疗,术后xelox方案3程。结合治疗中相关实验室指标和临床症状,开展正常组织损伤的临床和剂量体积因素分析。结果患者术前肝脏、肾脏和十二指肠损伤发生率分别为22%、48%和33%;治疗结束后肝脏和肾脏损伤发生率分别为35%和49%。所有肝、十二指肠损伤经对症处理后均不影响治疗,肾损伤不需特殊处理可恢复正常。分析提示术前放化疗较术前化疗增加肝损伤发生率(P=0.00、0.03),而肾损伤仅与放疗前肾小球滤过率相关(P=0.80、0.13)。肝V3.5≤98.96%,十二指肠D2 cm³≤48 Gy。结论胃癌术前放化疗方案是安全的。术前放化疗较术前化疗未增加肾损伤风险,但有加重肝损伤趋势,值得重视和改进。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	冯玲玲
	张玉晶
	张黎
	黄劭敏
	周志伟

关键词 ：胃肿瘤/术前放化疗法, 胃肿瘤/三维放射疗法, 正常组织损伤, 剂量效应

Abstract：

Objective To investigate the clinical and dose-volume factors for damages to organs at risk (OARs) during preoperative chemoradiotherapy for gastric cancer, and to provide a reference for optimization of radiotherapy plans to avoid or reduce damages to OARs. Methods A total of 58 patients with locally advanced gastric adenocarcinoma undergoing neoadjuvant treatment were enrolled as subjects. In those patients, 30 received preoperative chemoradiotherapy combined with surgery and adjuvant chemotherapy, while others received preoperative chemotherapy combined with surgery and adjuvant chemotherapy. The preoperative chemotherapy group received 2-3 cycles of xeloxregimen (capecitabine+oxaliplatin) before surgery and 3-4 cycles of xeloxregimen after surgery (a total of 6 cycles). The preoperative chemoradiotherapy group received preoperative radiotherapy (45 Gy in 25 fractions) combined with 2 cycles of concurrent xeloxchemotherapy at 14-21 days after the first cycle of xeloxregimen, as well as 3 cycles of xeloxchemotherapy after surgery. The analyses of clinical and dose-volume factors for damages to OARs were performed based on laboratory indices and clinical symptoms during the treatment. Results In all the patients, the incidence rates of liver injury (LI), renal injury (RI), and duodenum injury (DI) before surgery were 22%,48%, and 33%, respectively;the incidence rates of LI and RI after treatment were 35% and 49%, respectively. After appropriate treatment, neither LI nor DI affected the treatment of gastric cancer. RI healed without any special treatment. Compared with preoperative chemotherapy, preoperative chemoradiotherapy caused higher incidence of LI (P=0.00,0.03).RI was only associated with glomerular filtration rate before radiotherapy (P=0.08,0.13). A V3.5 of ≤98.96% for the liver reduced LI, while a D2cc of ≤48 Gy for the duodenum reduced DI. Conclusions Preoperative chemoradiotherapy is safe for treating gastric cancer. Compared with preoperative chemotherapy, preoperative chemoradiotherapy does not increase the risk of RI. However,preoperative chemoradiotherapy tends to increase LI.Further studies are needed to improve the treatment method.

Key words： Gastric neoplasms/preoperative chemoradiotherapy Gastric neoplasms/three-dimentional radiotherapy Injury of normal tissue Dose-effect

收稿日期: 2017-06-13

基金资助:

中山大学临床医学研究5010计划(2012013)

通讯作者: 张玉晶,Email:zhangyj@sysucc.org.cn

引用本文:

冯玲玲,张玉晶,张黎等. 胃癌术前放化疗正常组织放射损伤的剂量效应分析[J]. 中华放射肿瘤学杂志, 2018, 27(3): 271-276.

Feng Lingling,Zhang Yujing,Zhang Li et al. A dose-effect analysis of organs at risk during preoperative chemoradiotherapy for gastric cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(3): 271-276.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.03.009 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I3/271

[1] Ajani JA,Rodriguez W,Bodoky G,et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J ClinOncol,2010,28(9):1547-1553.DOI:10.1200/JCO.2009.25.4706.
[2] Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastriccancer (SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.DOI:10.1016/S1470-2045(08)70035-4.
[3] Trip AK,Poppema BJ,Van Berge MI,et al. Preoperative chemoradiotherapy in locally advanced gastric cancer,a phase Ⅰ/Ⅱ feasibility and efficacy study[J].RadiotherOncol,2014,112(2):284-288.DOI:10.1016/j.radonc.2014.05.003.
[4] Pera M,Gallego R,Montagut C,et al. Phase Ⅱ trial of preoperative chemoradiotherapy with oxaliplatin,cisplatin,and 5-FU in locally advanced esophageal and gastric cancer[J].Ann Oncol,2012,23(3):664-670.DOI:10.1093/annonc/mdr291.
[5] Leong T,Smithers BM,Haustermans K,et al. TOPGEAR:arandomized,phase Ⅲ trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer:interim results from an international,intergroup trial of the AGITG,TROG,EORTC and CCTG[J].Ann SurgOncol,2017,24(8):2252-2258.DOI:10.1245/s10434-017-5830-6.
[6] Macdonald JS,Smalley SR,Benedetti J,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J].N Engl J Med,2001,345(10):725-730.DOI:10.1056/NEJMoa010187.
[7] NCCN. NCCN clinical practice guidelines in oncology,antiemesis,(version1.2017)[M].NCCN,2017.
[8] Matzinger O,Gerber E,Bernstein Z,et al. EORTC-ROG expert opinion:radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach[J].RadiotherOncol,2009,92(2):164-175.DOI:10.1016/j.radonc.2009.03.018.
[9] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Am J Kidney Dis,2002,39(2 Suppl 1):S1-S266.
[10] Chakravarty T,Crane CH,Ajani JA,et al. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma[J].Int J RadiatOncolBiolPhys,2012,83(2):581-586.DOI:10.1016/j.ijrobp.2011.07.035.
[11] Li GC,Wang JZ,Hu WG,et al. Radiation-induced liver injury in three-dimensional conformal radiation therapy (3D-CRT) for postoperative or locoregional recurrent gastric cancer:risk factors and dose limitations[J/OL].PLoS One,2015,10(8):e0136288.DOI:10.1371/journal.pone.0136288.
[12] Liang SX,Zhu XD,Xu ZY,et al. Radiation-induced liver disease in three-dimensional conformal radiation therapyfor primary liver carcinoma:the risk factors and hepatic radiation tolerance[J].Int J RadiatOncolBiolPhys,2006,65(2):426-434.DOI:10.1016/j.ijrobp.2005.12.031.
[13] Kawashima M,Kohno R,Nakachi K,et al. Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma[J].Int J RadiatOncolBiol Phys,2011,79(5):1479-1486.DOI:10.1016/j.ijrobp.2009.12.048.
[14] Yavas G,Elsurer R,Yavas C,et al. Basal renal function reserve and mean kidney dose predict future radiation-induced kidney injury in stomach cancer patients[J].Support Care Cancer,2014,22(2):445-451.DOI:10.1007/s00520-013-1996-z.
[15] Feehally JF,Floege J.Comprehensive clinicalnephrology[M].3rd ed. Philadelphia,PA:Mosby/Elsevier,2007:27-34.
[16] Trip AK,Nijkamp J,Van Tinteren H,et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer[J].RadiotherOncol,2014,112(2):289-294.DOI:10.1016/j.radonc.2014.08.039.
[17] Diavolitsis VM,Rademaker A,Boyle J,et al. Change in creatinine clearance over time following upper abdominal irradiation:a dose-volume histogram multivariate analysis[J].Am J ClinOncol,2011,34(1):53-57.DOI:10.1097/COC.0b013e3181 d27080.
[18] Jansen EPM,Saunders MP,Boot H,et al. Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer[J].Int J RadiatOncolBiolPhys,2007,67(3):781-785.DOI:10.1016/j.ijrobp.2006.09.012.
[19] K st S,D rr W,Keinert K,et al. Effect of dose and dose-distribution in damage to the kidney following abdominalradiotherapy[J].Int J RadiatBiol,2002,78(8):695-702.DOI:10.1080/09553000210134791.
[20] Minn AY,Hsu A,La T,et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer[J].Cancer,2010,116(16):3943-3952.DOI:10.1002/cncr.25246.
[21] Chon YE,Seong J,Kim BK,et al. Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma:endoscopic findings and risk factors[J].Int J Radiat OncolBiolPhys,2011,81(5):1343-1351.DOI:10.1016/j.ijrobp.2010.07.1986.
[22] Prior P,Tai A,Erickson B,et al. Consolidating duodenal and small bowel toxicity data via isoeffective dose calculations based on compiled clinical data[J].PractRadiatOncol,2014,4(2):e125-e131.DOI:10.1016/j.prro.2013.05.003.
[23] Shinoto M,Shioyama Y,Matsunobu A,et al. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer[J].RadiotherOncol,2016,120(1):140-144.DOI:10.1016/j.radonc.2016.04.040